For patients seeking more than standard oxygen therapy, our myAirvo 3 high-flow nasal therapy system takes COPD care to the next level. This isn’t just about delivering oxygen — it’s about smart, connected respiratory support that blends comfort, monitoring and clinical insight for improved outcomes.

Key features & benefits:

• Bluetooth and modem connectivity allow live-streaming of therapy data directly to your clinician. You’ll have real-time visibility into usage time, flow rates, respiratory rate and oxygen saturation — meaning fewer visits, better oversight, and more freedom in your daily life.
  
  
• Built for home therapy: Designed for use 4-8 hours per day or overnight, this humidified high-flow system helps reduce exacerbations, ease breathlessness, and improve sleep quality.
  
  
• Strong evidence base:
  
  A feasibility study found that using home HFNT for up to 3 months in COPD patients after hospitalisation was feasible and showed improvements in disease-specific quality of life.
  Source
  
  A major multi-centre, randomised controlled trial (the “HiFlo COPD” study) is underway with the myAirvo 3, testing whether use in-home increases time to first moderate or severe exacerbation or all-cause mortality in moderate to very severe COPD (GOLD III–IV).
  
  
• Comfort meets performance: The system delivers warmed, humidified respiratory gas via special nasal interface (Optiflow + Duet) at high flow rates (20-35 L/min in trials) and has daily remote monitoring capability built in.
  Source
  
  
• Optimised for COPD care: If you are using long-term oxygen or have frequent flare-ups, this system is designed to reduce hospitalizations, lessen dyspnoea and improve quality of life — supported by the growing evidence base.